6.3M
Downloads
252
Episodes
Have a menopause question? You’ll find the answers here. Join me, GP and Menopause Specialist Dr Louise Newson, for the definitive perimenopause and menopause podcast. Each week I’m joined by a special guest for the lowdown on the latest research and treatments, bust myths and share inspirational stories. This podcast is brought to you by the Newson Health Group, which has clinics across the UK dedicated to providing personalised perimenopause and menopause care for all women. It funds cutting-edge menopause research and creates clinical-led education programmes for healthcare professionals. It also funds the award-winning balance menopause support app, which provides free menopause resources and support to millions of people worldwide, empowering and enabling women to have choice and control over their perimenopause and menopause treatment.
Episodes
Tuesday Feb 20, 2024
244 - Hot flush drug fezolinetant
Tuesday Feb 20, 2024
Tuesday Feb 20, 2024
On this week’s podcast, Dr Louise is joined by Dr Ashley Winter, a urologist and sexual medicine specialist, and Dr Sarah Glynne, a GP and menopause specialist who is a member of the research team at Newson Health and chairs a working party that promotes access to evidence-based menopause care for patients with breast cancer.
They discuss Fezolinetant – brand name Veoza – a new drug recently approved in the UK and other countries to treat moderate to severe hot flushes in menopausal women aged 45 to 60 years.
You can read an article about fezolinetant on the balance website here.
Related articles
Lederman S., Ottery F.D., Cano A., Santoro N., Shapiro M., Stute P., et al. (2023) 'Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study', Lancet, 401(10382):1091-102. doi.org/10.1016/S0140-6736(23)00085-5
Johnson K.A., Martin N., Nappi R.E., Neal-Perry G., Shapiro M., Stute P., et al. (2023), 'Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a Phase 3 RCT', J Clin Endocrinol Metab, 108(8):1981-97. Doi:10.1210/clinem/dgad058
Douxfils J., Beaudart C., Dogne J.M. (2023), 'Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant', Lancet, 402(10413):1623-5. doi.org/10.1016/S0140-6736(23)01634-3
Follow Dr Ashley Winter on X and Instagram @ashleygwinter
Follow Dr Sarah Glynne on Instagram @sarahglynne
Click here to find out more about Newson Health
Comments (1)
To leave or reply to comments, please download free Podbean or
As a GP with interest in the Menopause, this is fascinating. The safety data is really concerning.
Wednesday Feb 21, 2024
To leave or reply to comments,
please download free Podbean App.